Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors

Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors

Abstract Background While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of circulating tumor DNA (ctDNA) as a modality of th...

Full description

Bibliographic Details
Main Authors: Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Shogen Boku, Toshihiro Kudo, Yoshiyuki Yamamoto, Akiyoshi Kanazawa, Tadamichi Denda, Masahiro Goto, Naoko Iida, Hiroshi Ozaki, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Yoichi Naito, Takayuki Yoshino
Format: Article
Language:English
Published: Nature Portfolio 2024-07-01
Series:BJC Reports
Online Access:https://doi.org/10.1038/s44276-024-00073-7

Internet

https://doi.org/10.1038/s44276-024-00073-7

Similar Items